Choroidal neovascularization associated with West Nile virus chorioretinitis.
A case of late-onset choroidal neovascularization in a patient with a history of West Nile virus chorioretinitis is described. An 86-year-old man with a history of diabetes mellitus developed bilateral West Nile virus chorioretinitis in 2001, after which his vision improved to baseline. Approximately 5 years later, the patient was found to have choroidal neovascularization in his left eye, for which he received an intravitreal injection of bevacizumab. After one injection, there was good anatomical response. Choroidal neovascularization may be a late-onset complication of West Nile virus chorioretinitis, and bevacizumab may be a good therapeutic option.
Seth
Rajeev K
RK
Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT 06520, USA.
Stoessel
Kathleen M
KM
Adelman
Ron A
RA
D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002825:Chorioretinitis / Q000150:complications* / Q000821:virology*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D003930:Diabetic Retinopathy / Q000150:complications; D005654:Fundus Oculi; D006801:Humans; D008297:Male; D010211:Papilledema / Q000175:diagnosis / Q000209:etiology; D013997:Time Factors; D041623:Tomography, Optical Coherence; D014901:West Nile Fever
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab